Dr Anirban Majumder, MBBS, MD, DM. - KPC Medical College, Kolkata, India -  Professor

Dr Anirban Majumder

MBBS, MD, DM.

KPC Medical College, Kolkata, India

Professor

KOLKATA, West Bengal | India

Main Specialties: Endocrinology Diabetes & Metabolism

Additional Specialties: Endocrinology

ORCID logohttps://orcid.org/0000-0001-6937-8675


Top Author

Dr Anirban Majumder, MBBS, MD, DM. - KPC Medical College, Kolkata, India -  Professor

Dr Anirban Majumder

MBBS, MD, DM.

Introduction

1. Professor in Department of Endocrinology, of KPC Medical College and Hospital, Jadavpur, Kolkata.

2. Regional Faculty for Certificate Course in Evidence Based Diabetes Management, of Public Health Foundation of India, New Delhi, (2010-18).

3. Faculty for Integrated Diabetes and Endocrine Certificate Course (IDECC), affiliated by The University Of Newcastle, Australia (2016 – 2018).

4. Publications: 43 in National & International Journals

5. Clinical Guide for PhD under University of Calcutta.

Primary Affiliation: KPC Medical College, Kolkata, India - KOLKATA, West Bengal , India

Specialties:

Additional Specialties:

Research Interests:


View Dr Anirban Majumder’s Resume / CV

Education

Jan 1994 - Jan 1997
Institute of Postgraduate Medical Education and Research
DM
ENDOCRINOLOGY
Apr 1992
University College of Medicine, Calcutta University
M.D.
General Medicine
Apr 1992
University College of Medicine, Calcutta University,
M.D.
General Medicine
Jan 1989 - Jan 1991
University of Calcutta
MD
MEDICINE
Jun 1986
R. G. Kar Medical College, Calcutta University
M.B.B.S.
Jan 1981 - Jan 1986
RG Kar Medical College
MBBS

Experience

Feb 2014
KPC Medical College and Hospital, Jadavpur, Kolkata.
Professor
Department of Endocrinology
Jan 2007 - Jan 2009
KPC Medical College and Hospital
Assistant Professor
Department of Medicine
Jan 2005 - Jan 2007
Vivekananda Institute of Medical Sciences
Assistant Professor
Endocrinology
Jan 2002 - Jan 2004
University of Newcastle Australia
Conjoint Faculty (Facilitator in India)
Graduate Diploma in Diabetes Care
KPC Medical College and Hospital
Associate Professor
Endocrinology

Publications

49Publications

394Reads

2Profile Views

14PubMed Central Citations

A Retrospective Study to Examine the Correlation of Bioelectrical Impedance Analysis with Shear-wave Elastography in Indian Patients with Non-Alcoholic fatty Liver Disease And diabetes on Background Sodium-glucose Cotransporter-2 Inhibitor Therapy

Roy S, Majumder A (May 15, 2019)

Correlation of Bio-electrical Impedance Analysis with Shear-Wave Elastography

Patients with non-alcoholic fatty liver disease (NAFLD) are often insulin resistant. Several recent studies show NAFLD to be associated with cardiovascular risk. Bioimpedance analysis (BIA) is a common approach for body composition measurements and is a noninvasive, low-cost modality. Shear-Wave elastography (SWE) works using an acoustic radiation force pulse sequence that generates shear waves that estimates the liver stiffness.

View Article
May 2019

Effects on Metabolic Parameters of Addition of SGLT-2 Inhibitors on Patients with Type 2 Diabetes Inadequately Controlled with DPP-IV Inhibitors and Metformin

Diabetes Obes Int J 2019, 4(2):000201

Diabetes And Obesity International Jounal

Background: Practice guidelines are open regarding choice of therapy after metformin. The second lines's agent insulin (INS), sulphonylureas (SU) and thiazolidinediones (TZD) may cause either hypoglycemia or weight gain. Dipeptidyl peptidase-IV (DPP4) inhibitors are unlikely to produce that. Sodium- glucose transporter-2 (SGLT-2) inhibitors are newer agents with the advantage of weight loss. Indian data regarding combination therapy with Metformin with DPP-4 inhibitors plus SGLT-2 inhibitors are scanty; hence this study is relevant. Moreover the number of patients studied, duration of study, study variables and effects of three SGLT-2 inhibitors are analysed separately. Objectives: To study the glycaemic and other metabolic parameters after treatment with SGLT-2 inhibitors-canagliflozin or, dapagliflozin or, empagliflozin in type 2 Diabetes (T2DM) patient inadequately controlled (HbA1c >7.5%) with DPP-4 inhibitors plus metformin. Methodology: Data of 101 T2DM patients inadequately controlled (HbA1c>7.5%)  with DPP-4 inhibitors plus metformin who were prescribed canagliflozin 100 mg or, dapagliflozin 5 or 10 mg or empagliflozin 10 mg or 25 mg once  daily with mean follow-up duration of 23 weeks were analysed. Subjects receiving INS, SU and TZD were excluded from analysis. Changes in weight, blood pressure, glycaemia, lipids,  renal and hepatic parameters were studied. Subgroup analysis were done to see effects of three SGLT-2 inhibitors. Results: Results showed that addition of SGLT-2 inhibitors produced favourable effects on all metabolic parameters studied.

View Article
May 2019
1 Read

Liraglutide - Indian Experience.

Indian J Endocrinol Metab 2018 Nov-Dec;22(6):818-826

Department of Medical Sciences, JJT University, Rajasthan, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijem.IJEM_187_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330852PMC
February 2019
17 Reads

First fabulous Fifty -An Initial Experience of Duraglutide from a Tertiary Care Centre in Eastern India

Endocrinal Diabetes Metab J, volume 2 (4): 1-5, 2018

Endocrinology, Diabetes And Metabolism Journal

Objective: This retrospective single centred real world observational study was undertaken with the aim to introspect the glycaemic control, weight loss, changes in lipid parameters, adverse events and treatment adherence with Dulaglutide therapy. Methodology: Single centred, retrospective, real world, observational study conducted on subjects taking liraglutide for a mean duration of 41 weeks in the endocrine out-patient department. Results: Data of 45 subjects were available.

View Article
November 2018

Beginning With Very LOw Dose (0.2 mg) Liraglutide in Indian Type 2 Diabetic Patients Appears Better Tolerated: Experience from Real Life Practice.

J Diabetes Metab Disord Control 2017, 4(6): 00127

Journal of Diabetes, Metabolic Disorders & Control

Background: The gastrointestinal (GI) intolerance is important deterrents to adherence and long-term compliance of liraglutide, a human glucagon-like peptide-1 (GLP-1) receptor agonist. To overcome this troublesome adverse effect, liraglutide in 0.2 mg per day was used as starting dose and weekly up-titrated to 0.6 mg per day. Aim: To assess the efficacy and tolerability of very low dose (0.2 mg) of liraglutide versus usual dose (0.6 mg) liraglutide as a starting dose in obese uncontrolled longstanding Indian type 2 diabetes patients (T2D). Settings And Design: A single centered, retrospective observational study conducted for 24 weeks in a real world setting.

View Article
December 2017
1 Read

Occurrence and risk factors of peripheral artery disease in type 2 diabetes: an eastern India perspective

Journal of the Indian Medical Association, November 2017; Vol 115: 41-44.

Journal of the Indian Medical Association

View Article
November 2017
6 Reads

Pattern of dyslipidemia, burden and treatment outcomes in type-2 diabetes: an eastern India perspective.

Journal of the Indian Medical Association, November 2017; Vol 115: 49- 53.

Journal of the Indian Medical Association

View Article
November 2017
3 Reads

Consensus on "Basal insulin in the management of Type 2 Diabetes: Which, When and How?"

J Assoc Physicians India. 2017 Jul;65(7):51-62

The Journal of Association of Physicians in India.

INTRODUCTION: Type 2 diabetes mellitus (T2DM) has attained epidemic proportions and continues to increase despite the availability of a number of oral antidiabetic medications and major advances made in insulin delivery since its discovery nearly a hundred years ago. One, amongst many other reasons responsible for the inability to achieve adequate glycaemic control in a substantial proportion of T2DM patients is the delayed initiation and inappropriate intensification of insulin treatment. Appropriate initiation and intensification of insulin is critical for the successful achievement of tight glycaemic control. OBJECTIVE: To provide simple and easily implementable guidelines to primary care physicians on basal insulin initiation and intensification, along with use of basal insulin in special situations (hepatic failure, renal failure and gestational diabetes mellitus). METHODS: Each consensus statement on basal insulin initiation, intensification and use of basal insulin in special situations was evaluated for dosing and titration based on established guidelines, data from approved pack inserts, prescribing information or summary of product characteristics for each insulin type, and published scientific literature. These evaluations were then factored into the national context based not only on the clinical experience of the expert committee representatives' but also based on the common therapeutic practices followed in India to successfully achieve optimal glucose control. RESULTS: Recommendations on initiation and intensification of basal insulin, and its use in special situations, have been developed. The key recommendations are to initiate basal insulin when 2 or 3 oral antidiabetic medications fail to achieve target glycaemic control, or in symptomatic patients with glycated haemoglobin value greater than 9%. Depending upon patient characteristics, any of the four available basal insulins [Neutral protamine Hagedorn (NPH), Glargine (IGlar), Detemir (IDet), Degludec (IDeg)] can be used. However, IDeg has a longer duration of action, comparatively lesser hypoglycaemia (both overall and nocturnal) and more flexibility in administration timing compared to IGlar) and IDet. Inability to maintain glycaemic control should lead to prompt intensification of basal insulin treatment by adding mealtime insulin, consisting of one to three injections of either rapid-acting insulin analog or regular insulin; depending upon patient characteristics, intensification can also be achieved by transition from basal insulin to twice daily premixed insulin analogs/premixed human insulin/insulin co-formulations. IDeg/IDet can be used in all grades of renal and hepatic impairment; and IDet has been approved for use in gestational diabetes mellitus. CONCLUSIONS: We hope that these consensus based recommendations shall be a useful reference tool for health care practitioners and help them in initiating and intensifying insulin therapy in T2DM patients in order to achieve optimal glycaemic control.

View Article
July 2017
1 Read

Hypoparathyroidism Presenting as Movement Disorder and Seizure in a Case of Post- Surgical Hypothyroidism

American Journal of Medical Case Reports, vol. 5, no. 3 (2017): 53-55. doi: 10.12691/ajmcr-5-3-2

American Journal of Medical Case Reports

http://pubs.sciepub.com/ajmcr/5/3/2/index.html

View Article
March 2017
8 Reads

Thyroid profile and autoantibodies in Type 1 diabetes subjects: A perspective from Eastern India.

Indian J Endocrinol Metab 2017 Jan-Feb;21(1):45-50

Department of Endocrinology, Park Clinic, Kolkata, West Bengal, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/2230-8210.195998DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240080PMC
February 2017
16 Reads
1 Citation

Outcome and preferences in male-to-female subjects with gender dysphoria: Experience from Eastern India.

Indian J Endocrinol Metab 2017 Jan-Feb;21(1):21-25

Department of Medicine, Endocrinology Unit, K P C Medical College, West Bengal University of Health Sciences, Kolkata, West Bengal, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/2230-8210.196000DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240066PMC
February 2017
123 Reads

Outcome and Preferences in male-to-female Subjects with Gender Dysphoria: Experience from Eastern India

Indian J Endocr Metab 2017, 21:21-5

Indian Journal of endocrinology & Metabolism

Context: Gender dysphoria (GD) is an increasingly recognised medical condition in India, and little scientific data on treatment outcomes are available. Aims: Our objective is to study the therapeutic options including psychotherapy, hormone and surgical treatments used for alleviating GD in male-to-female (MTF) transgender subjects in Eastern India. Subjects and Methods: This is a retrospective study of treatment preferences and outcome in 55 MTF transgender subjects who were presented to the endocrine clinic. Statistical Analysis Used: Descriptive statistical analysis is carried out in the present study, and Microsoft word and Excel are used to generate graphs and tables. Results: The mean follow up was 1.9 years and 14 subjects (25.5%) were lost to follow-up after a single or 2-3 contact sessions. Rest 41 subjects (74.5%) desiring treatment had regular counselling and medical monitoring. All 41 subjects were dressing to prepare herself as female and all of them were receiving cross-sex hormone therapy either estrogen only (68%), or drospiremone in combination with estrogen (12%), or gonadotropin-releasing hormone agonist (GnRH) in combination with estrogens (19.5%). Most of the subjects preferred estrogen therapy as it was most affordable and only a small number of subjects preferred drospiremone or GnRH agonist because of cost and availability. 23.6% subjects underwent esthetic breast augmentation surgery and 25.5% underwent orchiectomy and/or vaginoplasty. Three subjects presented with prior breast augmentation surgery and nine subjects presented with prior orchiectomy without vaginoplasty, depicting a high prevalence of poorly supervised surgeries. Conclusions: Standards of care documents provide clinical guidance for health professionals about the optimal management of transsexual people. The lack of information among health professionals about proper and protocolwise management leads to suboptimal physical, social and sexual results.

View Article
January 2017
1 Read

Thyroid profile and autoantibodies in Type 1 diabetes subjects: A perspective from Eastern India

Indian J Endocr Metab 2017;21:45‑50

Indian Journal of Endocrinology and Metabolism

Context: There has been a rise in the incidence of type 1 diabetes mellitus (T1DM) in India. The prevalence of thyroid autoantibodies and thyroid dysfunction is common in T1DM. Aims: The aim of this study is to determine the incidence of thyroid dysfunction and thyroid autoantibodies in T1DM subjects, without any history of thyroid disease, and the prevalence of glutamic acid decarboxylase (GAD) antibody, Islet antigen‑2 antibody (IA2), thyroid peroxidase (TPO), and thyroglobulin autoantibodies (Tg‑AB) in T1DM subjects. Settings and Design: This was a cross‑sectional clinical‑based study. Subjects and Methods: Fifty subjects (29 males, 31 females) with T1DM and without any history of thyroid dysfunction were included in the study. All subjects were tested for GAD antibody, IA2 antibody, TPO antibody, thyroglobulin antibody, free thyroxine, and thyroid‑stimulating hormone. Statistical Analysis Used: A Chi-square/pooled Chi-square test was used to assess the trends in the prevalence of hypothyroidism. A two-tailed P < 0.05 was considered statistically significant. Results: The mean age of the subjects was 23.50 years. 9.8% of subjects were below the age of 12 years, 27.45% of subjects were of age 12–18 years, 37.25% of subjects were of age 19–30 years, and 25.49% of subjects were above 30 years. 78% were positive autoantibody for GAD, 30% for IA‑2, 24% for TPO, and 16% were positive for Tg‑AB. A total of 6.0% of T1DM subjects had evidence of clinical hypothyroidism, but the prevalence of subclinical hyperthyroidism (SCH) varied from 32% to 68.0% for we considered different definitions of SCH as advocated by different guidelines. All subjects with overt hypothyroidism had positive GAD and thyroid autoantibodies. One (2%) subject had clinical hyperthyroidism with strongly positive GAD, TPO, and Tg‑AB. Conclusions: We found a high prevalence of GAD, IA2, TPO, and Tg‑AB in our T1DM subjects. A substantial proportion of our subjects had undiagnosed thyroid dysfunction with a preponderance of subclinical hypothyroidism. All T1DM subjects with overt hypothyroidism or hyperthyroidism had positive GAD and thyroid autoantibodies. The high prevalence of undiagnosed thyroid dysfunction highlights the importance of regular thyroid screening in T1DM subjects.

View Article
January 2017
1 Read

A study to evaluate the prevalence of hypogonadism in Indian males with Type‑2 diabetes mellitus

Indian J Endocr Metab 2017;21:64‑70

Background: A high prevalence of hypogonadism in men with Type‑2 diabetes mellitus (T2DM) has been reported worldwide. Objectives: To evaluate the prevalence of hypogonadism in Indian males with T2DM and assess the primary and secondaryhypogonadism along with androgen deficiency. Materials and Methods: In this cross‑sectional study, 900 men with T2DM were evaluated using androgen deficiency in aging male questionnaire. They were screened for demographic characteristics, gonadal hormone levels, lipid profile, and glycosylated hemoglobin. Results: The prevalence of hypogonadism in T2DM patients was found to be 20.7% (186 out of 900). Hypogonadism was of testicular origin (primary) in 48/186 (25.8%) patients, of pituitary or hypothalamic origin (secondary) in 14/186 (7.53%), and remaining 124/186 (66.67%) patients were found to have low testosterone with theinappropriate normal level of luteinizing hormone and Follicle‑stimulating hormone. 451/900 (50.1%) patients were only symptomatic but had normal testosterone levels. Further 263 patients out 900 were asymptomatic, of which 51/900 (5.7%) patients had low levels of testosterone and 212/900 (23.5%) patients had normal testosterone level without symptoms. There were no deaths or other serious adverse events except mild pyrexia which was not related to the study. Conclusion: Hypogonadism diagnosis, at times, might not be validated with the help of androgen deficiency questionnaire or symptoms only. Given the large number of patients of T2DM in India, the incidence of hypogonadism is more in diabetic patients as compared to the general population. Hence, implementation of screening programs in diabetic patients is necessary to understand and detect individuals with low serum total testosterone at any early stage and to supplement testosterone accordingly. Key words: Androgen, diabetes mellitus, hypogonadism, testosterone

View Article
December 2016
13 Reads

LIRA 365 Plus-A Real World Experience of 19 Months Use of Liraglutide in the Obese Indian Type 2 Diabetic Subjects

Adv Obes Weight Manag Control 2016, 5(4): 00136

Advances in Obesity, Weight Management & Control

Background: Data from Indian sub-continent regarding the safety and efficacy of long term usage (one year and beyond) of liraglutide is scanty. The present study endeavors to share some data from a real world scenario. Aim: To evaluate the effect of liraglutide on body weight, blood pressure andglycemic control in obese Indian type 2 diabetic subjects. Methodology: Single centered, retrospective, real world, observational study conducted on subjects taking liraglutide for a period of 19 months in the endocrine out-patient department. Results: Data of 39 subjects were available for one year and beyond. Mean age was 47.89 ± 11 years. Mean duration of diabetes was 6.46 ± 4.55 years. Glycosylated hemoglobin (HbA1c) significantly decreased from 9.08 ± 1.54% at baseline to 7.26 ± 1.02% at end of therapy. Body weight significantly reduced from 88.27 ± 10.68 kg at baseline to 80.8 ± 11.83 kg at end of therapy and BMI significantlydeclined from 33.22 ± 4.5 to 31 ± 5.1 at end of therapy respectively. No majoradverse effects were reported. Conclusion: In our present study long term liraglutide therapy was associated with significant and sustained reduction in HbA1c and bodyweight. Liraglutide therapy, when tolerated for initial 3-6 months, was associated with minimal gastrointestinal side effects and no gastrointestinal adverse event related dropout. Liraglutide thus can be a natural choice of second line anti-diabetic agent in the subset of obese diabetic subjects. Keywords: Liraglutide; Obesity; Indian; Type 2 diabetes

View Article
December 2016
9 Reads

Outcome and preferences in female-to-male subjects with gender dysphoria: Experience from Eastern India.

Indian J Endocrinol Metab 2016 May-Jun;20(3):308-11

Department of Endocrinology, KPC Medical College, Jadavpur, Kolkata, West Bengal, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/2230-8210.179988DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855956PMC
May 2016
24 Reads
2 Citations

Outcome and preferences in female‑to‑male subjects with gender dysphoria: Experience from Eastern India

Indian J Endocr Metab 2016;20:308-11

Indian Journal of Endocrinology & Metabolism

Context: Awareness of gender dysphoria (GD) and its treatment is increasing. There is paucity of scientific data from India regarding the therapeutic options being used for alleviating GD, which includes psychotherapy, hormone, and surgical treatments. Aim: To study the therapeutic options including psychotherapy, hormone, and surgical treatments used for alleviating GD. Settings and Design: This is a retrospective study of treatment preferences and outcome in 18 female‑to‑male (FTM) transgender subjects who presented to the endocrine clinic. Results: The mean follow‑up was 1.6 years and only one subject was lost to follow‑up after a single visit. All subjects desiring treatment had regular counseling and medical monitoring. All FTM subjects were cross‑dressing. Seventeen (94.4%) FTM subjects were receiving cross‑sex hormone therapy, in the form of testosterone only (61.1%) or gonadotropin‑releasing hormone (GnRH) agonist in combination with testosterone (11.1%) or medroxyprogesterone acetate (MPA) depot in combination with testosterone (22.2%). FTM subjects preferred testosterone or testosterone plus MPA; very few could afford GnRH therapy. Testosterone esters injection was preferred by most (72.2%) subjects as it was most affordable while 22.2% chose 3 monthly injections of testosterone undecanoate for convenience and better symptomatic improvement, but it was more expensive. None preferred testosterone gels because of cost and availability concerns. About 33.3% of our subjects underwent mastectomy, 38.9% had hysterectomy with bilateral salpingo‑oophorectomy, and only one subject underwent phalloplasty. About 16.7% of FTM subjects presented with prior mastectomy depicting a high prevalence of unsupervised or poorly supervised surgeries not following protocol wise approach. Conclusion: Notwithstanding of advances in Standards of Care in the Western world, there is lack of awareness and acceptance in the FTM subjects, about proper and timely protocol‑wise management options leading to suboptimal physical, social, and sexual results. Key words: Female‑to‑male transsexuals, gender identity disorder, hormone and surgical treatments, India, psychotherapy

View Article
May 2016
5 Reads

Iodine Nutrition among the Pregnant and Lactating Women of Kolkata

J Hum Nutr Food Sci 4(1): 1078

Journal of Human Nutrition & Food Science

Abstract Objective: A cross-sectional study was carried out to assess the factors associated with iodine insufficiency among iodine deficient pregnant and lactating women. Materials and methods: The present study assessed urinary iodine excretion (UIE) in the spot urine samples from 237 pregnant women, 73 lactating mothers and 59 healthy non-pregnant female controls. The iodine content in household salt samples, method of salt storage and the method of cooking process of the study subjects, the effect of boiling on iodine content of salt were also estimated. Results: UIE value higher than 150 µg/l in pregnancy, higher than 100 µg/l in normal population and lactating women indicate adequate iodine nutrition. 37% pregnant women, 33% lactating women and 3% healthy non-pregnant female controls were iodine deficient. The household salt samples had poor iodine content (less than15ppm) among majority of these iodine insufficient pregnant women and iodine insufficient lactating women. However, 86% (n=76) iodine insufficient pregnant women and 75% (n=18) iodine insufficient lactating women were consuming branded iodised salt. 10% (n=9) Iodine insufficient pregnant woman, 8% (n=2) of iodine insufficient lactating woman and all iodine insufficient female control (n=2) were consuming salt from unbranded sources. Though most women used to add salt in the initial stages of cooking, 10% iodine sufficient pregnant women, 20% of iodine sufficient lactating women and 16% iodine sufficient female controls were adding salt in the middle or final stage of cooking. Loss of iodine from salt is negligible after simple boiling with water. Discussion: 37% pregnant women and 33% lactating women exhibited iodine insufficiency. Salt iodine content needs to be higher in India as the current level of iodine supplementation in India, i.e. 15 parts per million was not sufficient to meet the increased demand of pregnancy and lactation. However, when the actual salt iodine content was measured, it was less than15ppm among majority of the iodine insufficient pregnant women (65%), iodine insufficient lactating women (71%) and iodine insufficient female control (100%).The poor iodine content in salt contributes to the substantial gap between supply and demand that occurs in pregnant and lactating women. The iodine content of unbranded and branded salt and the method of salt storage are also important factors. Addition of salt at the beginning of the cooking process reduces iodine content of food. Pregnant women should receive iodine education to cover salt purchase and storage and add salt at the end of the cooking process. Conclusion: Salt iodine content, unbranded source of salt, method of salt storage and the cooking process are the important factors for iodine insufficiency in pregnant and lactating women of the study population. Keywords • Gestation • Iodine deficiency disorder • Pregnancy • Thyroid • Urinary iodine excretion

View Article
March 2016
5 Reads

Presentation of gender dysphoria: A perspective from Eastern India.

Indian J Endocrinol Metab 2016 Jan-Feb;20(1):129-33

Department of Endocrinology, KPC Medical College, Kolkata, West Bengal, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/2230-8210.172247DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743374PMC
February 2016
8 Reads

Ischaemic stroke leading to left hemiparesis, autohypophysectomy in a case of pituitary macroadenoma

JAPI, 1995; 43: 801-802

Mukherjee S N, Majumder A, Duttamunshi A K and Maji D

View Article
September 2015
2 Reads

A Case of Diabetes Mellitus and Hypercalcaemia

Published online first May 16,2015. http://dx.doi.org/10.15605/jafes.030.01.07

Journal of the ASEAN Federation of Endocrine Societies

Abstract We report a case of diabetes mellitus in a middle-aged female who subsequently developed primary hyperparathyroidism and underwent parathyroidectomy. Prior to surgery, she was hospitalized several times since 1988 for vomiting, pain abdomen and dehydration. On none of these occasions hypercalcaemia could be documented. Yet she developed pancreatic calcification and diabetes in 1991 and was diagnosed as fibrocalculous pancreatic diabetes (FCPD) and treated with insulin. Nephrolithiasis developed in 2003. Hypercalcaemia with high PTH was detected in 2004 and a solitary right parathyroid adenoma was identified and surgically removed. Following surgery, gastrointestinal symptoms disappeared but diabetes remained unaltered on follow up for 8 years. The cause of multiorgan calcification which started well before development of hypercalcaemia is not known. Key words: diabetes, hypercalcaemia, parathyroid adenoma

View Article
May 2015
9 Reads

Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes.

Sci Rep 2015 Jan 9;5:7706. Epub 2015 Jan 9.

Consultant Endocrinologist, Apollo Gleneagles Hospital, 58 Canal Circular Road, Kolkata 700054, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep07706DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287720PMC
January 2015
51 Reads
3 Citations
5.080 Impact Factor

Observational Study of Effects of Saroglitazar on Glycaemic and Lipid Parameters on Indian Patients with Type 2 Diabetes

Sci Rep. 2015; 5: 7706

Scientific Reports

Cardiovascular risk reduction is an important issue in the management of patients with Type 2 diabetes mellitus. Peroxisome proliferator activated receptor (PPAR) agonists favourably influence glycaemic and lipid parameters in patients with Type 2 diabetes and a dual PPAR agonist is expected to have favourable effect on both parameters. In this study we have analyzed the effect of Saroglitazar, a novel dual PPAR alpha & gamma agonist, on glycaemic and lipid parameters in Indian patients with Type 2 diabetes. After a mean follow-up period of 14 weeks in 34 patients, treatment with Saroglitazar, in a dose of 4 mg daily, resulted in significant improvement in both glycaemic and lipid parameters. There were significant mean reductions of fasting plasma glucose (36.71 mg/dl; p 5 0.0007), post-prandial plasma glucose (66.29 mg/dl; p 5 0.0005), glycosylated haemoglobin (1.13%; p , 0.0001), total cholesterol (48.16 mg/dl; p , 0.0001), low- density lipoprotein cholesterol (24.04 mg/dl; p 50.0048), triglyceride (192.78 mg/dl; p 50.0001), non-high density lipoprotein cholesterol (48.72 mg/dl; p , 0.0001) and the ratio of triglyceride and high density lipoprotein cholesterol (5.30; p 50.0006). There was no significant change in body weight, blood pressure, high-density lipoprotein cholesterol and serum creatinine.

View Article
January 2015
5 Reads

Severe Hypertriglyceridemia Presenting as Superior Sagittal Sinus Thrombosis

Jafes.029.02.14

Journal of the ASEAN Federation of Endocrine Societies

We report a case of a 38-year-old Indian male who presented with severe throbbing headache spreading diffusely from occipital to nuchal regions. He was detected to have superior cerebral (sagittal) venous sinus thrombosis (CVST) with severe hypertriglyceridemia without any coagulation abnormalities or autoimmune disease. Our case highlights the need for clinicians to consider CVST among patients with uncontrolled hypertriglyceridemia. New prognostic measures may become necessary having an implication on the risk of recurrence and duration of anticoagulant therapy in CVST. Key words: hypertriglyceridemia, venous thrombosis, headache

View Article
November 2014
5 Reads

Diabetic Dyslipidemia - Role of Saroglitazar

Majumder A, Chatterjee S (2014) Diabetic Dyslipidemia - Role of Saroglitazar. Med chem 4: 684-687. d

Medicinal chemistry

‘Diabetic dyslipidemia’ (combination of raised triglyceride levels, raised small-dense Low-density lipoprotein particles and low high-density lipoprotein cholesterol levels) is the most prominent risk factor of atherosclerosis and cardiovascular disease. Despite statin therapy and LDL-lowering, a high residual risk of cardiovascular events persists. High triglyceride levels and low high-density lipoprotein cholesterol levels singly and collectively increase the risk of cardiovascular events in type 2 diabetes mellitus and guidelines recommend modifying these secondary therapeutic targets to provide additional vascular protection.Addition of a fibrate or niacinareoptions for combination with a statin to reduce atherogenic dyslipidemia and are clearly effective at raising high-density lipoprotein cholesterol levels and lowering triglycerides.Addition of high dose omega-3 fatty acids (2-3 gm/day) with a statin are also effective in lowering triglyceride, but their effects on cardiovascular events remain uncertain and are complicated with safety issues. Saroglitazar is a novel dual Peroxisome Proliferator-Activated Receptors-α/γ agonist and the first glitazar approved in the world for the treatment of diabetic dyslipidemia by Drug Controller General of India in June 2013. Saroglitazar (2 mg and 4 mg) therapy has shown significant (45%) reduction in triglycerides, significant reduction of other atherogenic lipids (Low-density lipoprotein, very-low density lipoprotein, total cholesterol and apolipoprotein-B) and significant improvement of glycemic status, with relatively free from side effects. It has emerged with a hope to further reduce the incidence of cardiovascular disease among statin treated diabetic subjects. However, the trial populations were small and toxicity data may emerge with increasing use of this drug. Moreover, in absence of outcome studies and large multi-center longitudinal follow up data, the clinical cardiovascular efficacy is uncertain till date.

View Article
September 2014
8 Reads

Prevalence of iodine deficiency among pregnant and lactating women: Experience in Kolkata.

Indian J Endocrinol Metab 2014 Jul;18(4):486-90

Vivekananda Institute of Medical Sciences, West Bengal University of Health Sciences, Kolkata, West Bengal, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/2230-8210.137491DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138902PMC
July 2014
21 Reads
2 Citations

Prevalence of iodine deficiency among pregnant  and lactating women: Experience in Kolkata

Indian J Endocrinol Metab. 2014 Jul;18(4):486-90

Indian Journal of Endocrinology & Metabolism

Objective: The cross-sectional study was carried out to assess the iodine status of pregnant and lactating mothers, using median urinary iodine excretion (UIE) as the measure of outcome, to document the prevalence of iodine deficiency. Materials and Methods: The present study assessed the UIE in the morning urine samples from 237 pregnant women, 73 lactating mothers and 59 healthy non-pregnant female controls. Results: Out of 237 pregnant women, 88 (37%) exhibited insufficient iodine nutrition (UIE < 150 µg/l), out of 73 lactating mothers, 24 (33%) exhibited insufficient iodine nutrition (UIE < 100 µg/l) and only 3% female control subjects exhibited insufficient iodine nutrition (UIE < 100µg/l). Additionally, a number (32.3%) of babies born of iodine deficient mothers had respiratory distress at birth. Conclusion: It appears that the present salt iodination program is adequate for the general population but insufficient for the pregnant and lactating mothers. They need to be targeted with iodine supplements throughout pregnancy and lactation. Increased incidence of respiratory distress in the new born of iodine deficient mothers merits further study. Key words: Gestation, iodine deficiency, pregnancy, thyroid, urinary iodine excretion

View Article
July 2014
7 Reads

Discovery of insulin--from isletin to degludec and beyond.

J Indian Med Assoc 2013 Nov;111(11):729-32, 734

View Article

Download full-text PDF

Source
November 2013
81 Reads

Discovery of insulin--from isletin to degludec and beyond

J Indian Med Assoc. 2013 Nov;111(11):729-32, 734

Journal of the Indian Medical Association

In the year 1923, the Nobel Prize for Physiology and Medicine was awarded to Frederick Grant Banting and John James Rickard Macleod for discovery of Insulin. This discovery is among the greatest discoveries in the history of medicine. Isletin was the first and Degludec is the latest insulin to come to market. After discovery, subsequent research produced many more insulin and the process is ongoing. Here is a brief account on the history of insulin discovery and the subsequent research on insulin.

View Article
November 2013
12 Reads

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kolkata cohort of the A1chieve study

Majumder A, Singh AK, Gangopadhyay KK, Sen R, Shetty R, Majumdar S. Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kolkata cohort of the A1chieve study. Indian J Endocr Metab 2013;17:S584-7.

Indian Journal of Endocrinology and Metabolism

View Article
November 2013
7 Reads

Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting.

Indian J Endocrinol Metab 2013 Oct;17(Suppl 1):S301-3

Department of Endocrinology, KPC Medical College, Kolkata, West Bengal, India ; Department of Endocrinology, RTIICS, Kolkata, West Bengal, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/2230-8210.119629DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830340PMC
October 2013
10 Reads
1 Citation

Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting

Authors:
Sanyal D Majumder A

Indian J Endocr Metab, 2013;17:301-303

Indian J Endocr Metab

Liraglutide, a human glucagon-like peptide-1 receptor agonist, decreases glycosylated hemoglobin and causes weight loss. However, the cost of therapy and gastrointestinal side- effects such as nausea and diarrhea are important impediments to adherence and long-term compliance. We assessed the efficacy, safety and tolerability of low dose (0.6 mg) liraglutide in obese uncontrolled longstanding type 2 diabetes in Indian patients. Low dose liraglutide improved glycemic control and decreased weight. However, there was a significant drop out because of gastrointestinal intolerance and financial constraints.

View Article
October 2013
5 Reads

Peripheral neuropathy in diabetes.

J Indian Med Assoc 2013 Jun;111(6):382, 384-6

View Article

Download full-text PDF

Source
June 2013
2 Reads
1 Citation

Peripheral Neuropathy in Diabetes

JIMA 01 Jun 2013, 111(6):382, 384-6

Journal of the Indian Medical Association

Peripheral neuropathy is common complication of diabetes. The prevalence of peripheral neuropathy among diabetic patients on the basis of loss of vibration sensation had been studied. Detailed clinical history of each patient including age, gender, duration of diabetes, foot ulcer and biothesiometry was recorded in 211 diabetic patients between 20 and 80 years of age. It was observed that all patients under 30 years age (n = 8) felt vibration below 15 volts (no risk zone); 77% (24 out of 31) of the patients in the age group of 30-39 years were in the no risk zone, and 23% (n = 7) had mild peripheral neuropathy. Sixty per cent of the patients between 40 and 50 years (n = 44) were in the no risk zone, while 32% (n = 24) had mild peripheral neuropathy, 5% (n = 4) had moderate neuropathy and 3% (n = 2) had severe peripheral neuropathy. Amongst patients above 50 years of age, 31% (n = 31) were in no risk zone, 34% (n = 34) had mild peripheral neuropathy, 22% (n = 20) had moderate peripheral neuropathy and 13% (n = 13) had severe peripheral neuropathy. Of the patients with diabetes for less than 5 years, 58% had no neuropathy, and only 3% had severe neuropathy. Of the patients with diabetes for 5 to 15 years, 50% had no neuropathy, 30% had mild, and 10% had severe peripheral neuropathy. When patients with diabetes for over 15 years were studied, only 6% had no neuropathy and 19% had severe peripheral neuropathy. The study re-establishes that the severity of peripheral neuropathy increases with age and vibration perception decreses progressively with increased duration of diabetes. Vibration perception threshold testing helps to identify the high risk subjects who require special counselling and education to protect their feet.

View Article
June 2013
4 Reads

A case of simultaneous occurrence of Graves' disease and Hashimoto's thyroiditis.

Indian J Endocrinol Metab 2012 Dec;16(Suppl 2):S338-9

Department of medicine, KPC Medical College, Kolkata, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/2230-8210.104082DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603068PMC
December 2012
31 Reads
1 Citation

A case of simultaneous occurrence of Graves’ disease and Hashimoto’s thyroiditis

Indian J Endocr Metab 2012;16:S338-9

Indian Journal of Endocrinology & Metabolism

Introduction: Simultaneous occurrence of Hashimoto’s thyroiditis (HT), and Graves’ disease (GD) is rare. Aims and Objectives: We report a case of simultaneous occurrence of GD and HD, at presentation. Case Report: A 60-year-old lady presented with tremulousness of hands, palpitation, and excessive sweating. She had a history of weight loss and neck-swelling. Her weight was 46 kg, BMI 17, afebrile, regular pulse rate of 110/min with fine tremor in hands. Thyroid gland was symmetrically enlarged, firm, without any bruit, but mildly tender with lobular surface. There were no occular manifestations. Initial thyroid function tests (TFT) revealed: T3: 3.80 ng/ml (0.80-2.10), T4: 12.40 ug/dl (5.10-12), thyroid stimulating hormone (TSH): 0.20 μU/L (0.70–5). Her anti thyroperoxidase (TPO) antibody: 374 IU/ml (normal [nl.] <35) and TSH receptor antibody: 15 U/L (nl. <1) were both strongly positive. Ultrasonogram of thyroid revealed a hypoechoic enlarged gland. 99mTc pertechnetate scan showed an enlarged gland with increased uptake of radiocontrast: 17% (nl. 0.4-4%) with some patchy defects in both lower poles. Thyroid fine needle aspiration cytology (FNAC) showed sheets of Hurthle cells with abdunce of lymphocytes indicating HT. She was observed on beta blockers. Repeat TFT, 3 months later showed: T3: 4.20 ng/ml, T4: 14.40 ug/dl, TSH: 0.001 μU/L, with increased uptake on repeat scan. Conclusion: HT rarely occurs following GD. Our case of an elderly lady with no eye signs, lobular, firm tender goiter with patchy uptake in both lower poles on Tc99m scan were odd points in diagnosing isolated GD. FNAC confirmed simultaneous HD with GD. Key Words: Graves’ disease, Hashimoto’s thyroiditis, simultaneous

View Article
December 2012
6 Reads

Approach to the patient with persistent acromegaly after pituitary surgery.

J Clin Endocrinol Metab 2010 Sep;95(9):4114-23

Departments of Medicine and Neurosurgery, Stanford University School of Medicine, Stanford, California 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2010-0670DOI Listing
September 2010
6 Reads
3 Citations
6.210 Impact Factor

Xanthoma in a young woman with systemic lupus erythematosus.

Authors:
A Mujumder S N Roy

J Assoc Physicians India 1998 May;46(5):487-8

Department of Endocrinology and Metabolism, Institute of Post Graduate Medical Education and Research, 244, AJC Bose Road, Calcutta-700 020.

View Article

Download full-text PDF

Source
May 1998
4 Reads

Xanthoma in a young woman with systemic lupus erythematosus

The Journal of the Association of Physicians of India,01 May 1998, 46(5):487-488

Journal of Association of Physicians of India

View Article
May 1998
2 Reads

Graves disease in a woman with Sheehans syndrome

JAPI , 1997; 45 : 411 – 412

JAPI

View Article
September 1997
1 Read

Long-term complications and sexual dysfunctions in malnutrition related diabetes mellitus

Diabetologia , 1997 ; 40 ( Suppl 1 ) A 606

Diabetologia

View Article
May 1997
3 Reads

Clinical pattern of insulin requiring diabetes in Calcutta.

Journal Diab. Asso. India, 1996; 36: 70-76

Journal Diab. Asso. India

View Article
September 1996
5 Reads